Unraveling Autocrine Signaling Pathways Through Metabolic Fingerprinting in Serous Ovarian Cancer Cells
Overview
Authors
Affiliations
Focusing on defining metabolite-based inter-tumoral heterogeneity in ovarian cancer, we investigated the metabolic diversity of a panel of high-grade serous ovarian carcinoma (HGSOC) cell-lines using a metabolomics platform that interrogate 731 compounds. Metabolic fingerprinting followed by 2-dimensional and 3-dimensional principal component analysis established the heterogeneity of the HGSOC cells by clustering them into five distinct metabolic groups compared to the fallopian tube epithelial cell line control. An overall increase in the metabolites associated with aerobic glycolysis and phospholipid metabolism were observed in the majority of the cancer cells. A preponderant increase in the levels of metabolites involved in trans-sulphuration and glutathione synthesis was also observed. More significantly, subsets of HGSOC cells showed an increase in the levels of 5-Hydroxytryptamine, γ-aminobutyrate, or glutamate. Additionally, 5-hydroxytryptamin synthesis inhibitor as well as antagonists of γ-aminobutyrate and glutamate receptors prohibited the proliferation of HGSOC cells, pointing to their potential roles as oncometabolites and ligands for receptor-mediated autocrine signaling in cancer cells. Consistent with this role, 5-Hydroxytryptamine synthesis inhibitor as well as receptor antagonists of γ-aminobutyrate and Glutamate-receptors inhibited the proliferation of HGSOC cells. These antagonists also inhibited the three-dimensional spheroid growth of TYKNU cells, a representative HGSOC cell-line. These results identify 5-HT, GABA, and Glutamate as putative oncometabolites in ovarian cancer metabolic sub-type and point to them as therapeutic targets in a metabolomic fingerprinting-based therapeutic strategy.
Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.
Nadhan R, Kashyap S, Ha J, Jayaraman M, Song Y, Isidoro C Metabolites. 2023; 13(5).
PMID: 37233659 PMC: 10222714. DOI: 10.3390/metabo13050618.
Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications.
Ren X, Kang C, Garcia-Contreras L, Kim D Int J Mol Sci. 2023; 24(9).
PMID: 37175872 PMC: 10179437. DOI: 10.3390/ijms24098166.
Complex metabolic interactions between ovary, plasma, urine, and hair in ovarian cancer.
Zhong X, Ran R, Gao S, Shi M, Shi X, Long F Front Oncol. 2022; 12:916375.
PMID: 35982964 PMC: 9379488. DOI: 10.3389/fonc.2022.916375.
An R, Yu H, Wang Y, Lu J, Gao Y, Xie X Cancer Metab. 2022; 10(1):13.
PMID: 35978348 PMC: 9382832. DOI: 10.1186/s40170-022-00289-6.
Wu A, Liu J, Zhang X, Niu C, Shu G, Yin G Cancer Sci. 2022; 113(8):2627-2641.
PMID: 35639251 PMC: 9357658. DOI: 10.1111/cas.15447.